GWave
Hagar Technology is dedicated to revolutionizing diabetes management through innovative non-invasive glucose monitoring solutions. Their flagship product, GWave, utilizes radio frequency waves to continuously and accurately measure blood glucose levels, aiming to provide a painless, real-time alternative to traditional invasive methods. The company is focused on developing wearable devices, including a smartwatch-integrated sensor, to improve accessibility and quality of life for millions of people with diabetes worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Wearable non-invasive continuous glucose monitor (RF-based)
A wrist-worn/bracelet wearable sensor that uses radiofrequency waves and on-device analytics to continuously measure glucose levels in blood, transmitting results to a smartphone app and cloud service.
Wearable non-invasive continuous glucose monitor (RF-based)
A wrist-worn/bracelet wearable sensor that uses radiofrequency waves and on-device analytics to continuously measure glucose levels in blood, transmitting results to a smartphone app and cloud service.
Services
Design and conduct of clinical studies and proof-of-concept testing to evaluate wearable RF glucose sensors against reference glucose measurements and support regulatory submissions.
Business development and partnership engagement to transfer or license RF-based non-invasive glucose sensing technology to larger medical device companies for market-scale commercialization.
Design and conduct of clinical studies and proof-of-concept testing to evaluate wearable RF glucose sensors against reference glucose measurements and support regulatory submissions.
Business development and partnership engagement to transfer or license RF-based non-invasive glucose sensing technology to larger medical device companies for market-scale commercialization.
Expertise Areas
- Non-invasive continuous glucose sensing
- RF signal engineering and biosensing
- Machine learning for biosignal extraction
- Wearable device hardware design
Key Technologies
- Radiofrequency (RF) blood imaging for analyte detection
- Machine learning / signal processing for biosignals
- Bluetooth low-energy connectivity
- Smartphone application integration
News & Updates
Hagar is planning to put its GWave non-invasive continuous glucose monitoring technology in a smartwatch and eventually sell the technology to a larger medtech player that can market it globally.
Hagar raised $11.7 million in Series B funding led by Columbia Pacific to support the development and commercialization of GWave, a non-invasive glucose monitoring technology.
Hagar announced the closing of a $5 million Series C funding round, bringing total funding to $25 million, and showcased clinical findings at the ADA conference.
Hagar is planning to put its GWave non-invasive continuous glucose monitoring technology in a smartwatch and eventually sell the technology to a larger medtech player that can market it globally.
Hagar raised $11.7 million in Series B funding led by Columbia Pacific to support the development and commercialization of GWave, a non-invasive glucose monitoring technology.
Hagar announced the closing of a $5 million Series C funding round, bringing total funding to $25 million, and showcased clinical findings at the ADA conference.
Hagar is planning to put its GWave non-invasive continuous glucose monitoring technology in a smartwatch and eventually sell the technology to a larger medtech player that can market it globally.
Hagar raised $11.7 million in Series B funding led by Columbia Pacific to support the development and commercialization of GWave, a non-invasive glucose monitoring technology.
Hagar announced the closing of a $5 million Series C funding round, bringing total funding to $25 million, and showcased clinical findings at the ADA conference.
Hagar is planning to put its GWave non-invasive continuous glucose monitoring technology in a smartwatch and eventually sell the technology to a larger medtech player that can market it globally.
Hagar raised $11.7 million in Series B funding led by Columbia Pacific to support the development and commercialization of GWave, a non-invasive glucose monitoring technology.
Hagar announced the closing of a $5 million Series C funding round, bringing total funding to $25 million, and showcased clinical findings at the ADA conference.